Impact of A2 milk versus conventional milk on intestinal health: a proof-of-concept study in Irritable Bowel Syndrome patients

Impact of A2 milk versus conventional milk on intestinal health: a proof-of-concept study in Irritable Bowel Syndrome patients - A2 Milk Proof-of-concept

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON52571

Enrollment

Registered

2020-08-11

Start date

2022-08-08

Completion date

Unknown

Last updated

2024-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable Bowel Syndrome

Interventions

One 1-day intervention period subjects will ingest 200 mL A2 milk two times that day. In the other 1-day period intervention period, subjects will ingest 200 mL conventional milk two times that day.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Age between 18-70 years Based on Rome IV criteria, IBS-C or IBS-D predominant Indication that dietary components trigger GI symptoms

Exclusion criteria

Exclusion criteria: Abdominal surgery interfering with gastrointestinal function Lactose intolerance Cow's milk allergy Use of antibiotics in the 90 days prior to the study

Design outcomes

Primary

Measure	Time frame
Overall GI discomfort	—

Secondary

Measure	Time frame
Single GI symptoms Stool characteristics (frequency and consistency) BCM-7 in blood Effect of baseline characteristics on objectives	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)